September 25, 2020

The Niche

Knoepfler lab stem cell blog

Linda Marban

10 min read

The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with COVID-19. The reality is that that’s probably not going to happen. Even so, a whole range of people and firms are somewhat exaggerating and in a few cases outright …Read More

2 min read

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse this week as pharma giant J&J severed ties with the small California company (here and here). Capricor, which has received more than $17 million in CIRM grant funding, could …Read More

2 min read

Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made my stem cell predictions for 2014 and #3 on the list was “Big announcement  from “Big Pharma” on stem cells or regenerative medicine.” Chalk that up for the crystal ball of …Read More